STOCK TITAN
  1. Home
  2. Sec-filings
  3. INSP
  4. [8-K] Inspire Medical Systems, Inc. Reports Material Event

Inspire Medical Systems (INSP) shares June 26, 2026 investor presentation via 8-K

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Inspire Medical Systems, Inc. filed a Form 8-K to share that it will participate in meetings with investors and analysts in June 2026. The company is using a formal investor presentation for these meetings, which is provided as Exhibit 99.1 and posted on its investor relations website.

The presentation is furnished under Regulation FD, meaning it is for informational purposes and is not treated as filed financial statements or incorporated into other securities filings unless specifically referenced.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Regulation FD regulatory
"Item 7.01. Regulation FD Disclosure."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
Section 18 of the Securities Exchange Act of 1934 regulatory
"shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document."
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001609550False00016095502026-06-262026-06-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_________________________
CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 26, 2026
_________________________
INSPIRE MEDICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
_________________________
Delaware001-3846826-1377674
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
5500 Wayzata Blvd., Suite 1600
Golden Valley, Minnesota 55416
(Address of principal executive offices) (Zip Code)

(844) 672-4357
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareINSPNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 7.01.     Regulation FD Disclosure.

In June 2026, the Company will be participating in various meetings with investors and analysts, and a copy of the Company’s presentation materials being used at these meetings is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. These presentation materials are also available on the Investor Relations page of the Company’s website at https://investors.inspiresleep.com.

The information in Item 7.01 of this Current Report on Form 8-K and the presentation attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.Description
99.1
Inspire Medical Systems, Inc. Presentation dated June 26, 2026.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INSPIRE MEDICAL SYSTEMS, INC.
Date:June 26, 2026By:/s/ Matthew J. Osberg
Matthew J. Osberg
Chief Financial Officer

3

Source: View Original Filing on SEC EDGAR

FAQ

What did Inspire Medical Systems (INSP) disclose in this Form 8-K?

Inspire Medical Systems disclosed that it will participate in investor and analyst meetings in June 2026, using an investor presentation furnished as Exhibit 99.1 and posted on its investor relations website, providing a unified set of materials for those discussions.

What is included in Exhibit 99.1 for Inspire Medical Systems (INSP)?

Exhibit 99.1 contains Inspire Medical Systems’ investor presentation dated June 26, 2026. This presentation is used in meetings with investors and analysts and is also available on the company’s investor relations webpage for broader access to the same information.

How is the Inspire Medical Systems (INSP) investor presentation treated under securities laws?

The investor presentation furnished under Item 7.01 is not deemed filed for Section 18 of the Exchange Act. It is also not automatically incorporated into other Inspire Medical Systems filings unless specifically referenced, limiting associated liability and formal filing status.

Where can investors find the Inspire Medical Systems (INSP) June 2026 presentation?

Investors can access the June 2026 Inspire Medical Systems presentation, dated June 26, 2026, on the company’s investor relations website at https://investors.inspiresleep.com, as well as via Exhibit 99.1 attached to this Form 8-K filing.

Does this Inspire Medical Systems (INSP) Form 8-K include new financial statements?

The Form 8-K does not include new financial statements. It furnishes an investor presentation under Item 7.01 Regulation FD Disclosure, which is provided for informational purposes and is not treated as filed financial statements under Section 18 of the Exchange Act.

Filing Exhibits & Attachments

4 documents

Other Documents